BioCentury
ARTICLE | Clinical News

Lilly discontinues tabalumab for RA

February 8, 2013 3:00 AM UTC

Eli Lilly and Co. (NYSE:LLY) discontinued development of tabalumab to treat rheumatoid arthritis due to lack of efficacy in futility analyses of both the Phase III FLEX-M and FLEX-V trials in the indi...